Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arerugi = [Allergy]·2026
Same author

Algorithms in Allergy: Hereditary Angioedema.

Allergy·2026
Same author

International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema.

Allergy·2026
Same author

Treatment of Hereditary Angioedema With Plasma-Derived C1 Inhibitor: A Review.

Clinical and translational allergy·2025
Same author

Insights From the First 820 Patients From the Brazilian Multicenter Registry of Hereditary Angioedema: The Key Role of Genetic Testing and Targeted Therapies.

The journal of allergy and clinical immunology. In practice·2025
Same author

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.

The Journal of allergy and clinical immunology·2025
Same journal

Harnessing Machine Learning and Electronic Health Record Data to Improve Asthma Management.

Current allergy and asthma reports·2026
Same journal

Incorporating New Guidelines into School-Based Asthma Management.

Current allergy and asthma reports·2026
Same journal

The Modern Environment and Childhood Asthma: The Role of Air Pollution and Heavy Metal Exposure.

Current allergy and asthma reports·2026
Same journal

Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.

Current allergy and asthma reports·2026
Same journal

The Role of the Indoor Exposome in Food Allergy Development.

Current allergy and asthma reports·2026
Same journal

Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial Influences.

Current allergy and asthma reports·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Current management options for hereditary angioedema.

Konrad Bork1

  • 1Department of Dermatology, Johannes Gutenberg University, Mainz, Germany. bork@hautklinik.klinik.uni-mainz.de

Current Allergy and Asthma Reports
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Treatment for hereditary angioedema (HAE) involves managing acute attacks and preventing future ones. Several new therapeutic options are now available, significantly reducing the impact of HAE.

Related Experiment Videos

Last Updated: May 21, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling episodes.
  • HAE is caused by C1 esterase inhibitor deficiency (HAE-C1-INH).
  • Effective management of HAE is crucial to reduce patient burden.

Purpose of the Study:

  • To review current treatment strategies for HAE-C1-INH.
  • To highlight the expanding therapeutic landscape for HAE management.

Main Methods:

  • Review of available pharmacotherapies for HAE treatment.
  • Categorization of treatments into acute attack management and prophylaxis.
  • Inclusion of regional differences in treatment availability (Europe vs. United States).

Main Results:

  • Acute attack treatments include C1 inhibitor concentrates, bradykinin B2 receptor antagonists, recombinant C1-INH, plasma kallikrein inhibitors, and fresh frozen plasma.
  • Prophylactic options encompass C1-INH, attenuated androgens (danazol, stanozolol, oxandrolone), antifibrinolytics, and plasma-derived C1-INH concentrate.
  • Certain treatments like plasma-derived C1-INH and bradykinin B2 receptor antagonists are approved for self-administration and home use.

Conclusions:

  • The number of HAE management options has significantly increased recently.
  • These advancements contribute to diminishing the overall burden of HAE for patients.